Patrick Schöffski, MD, MPH, on RCC: Final Results of the EORTC 90101 CREATE Trial

Patrick Schöffski, MD, MPH, of Catholic University Leuven, discusses findings on the effect of crizotinib on disease control in patients with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification (Abstract 580).